GlassScriptPhysician profile
Sarah Glorioso
NPI 1093916140
$7,431.54
in general payments reported to CMS, 2019-2025
27 companies · $932 in 2025
The $932 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,933 · 2020: $430 · 2021: $588 · 2022: $1,004 · 2023: $1,374 · 2024: $1,170 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,131 · Education: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,130.58 |
| Education | $345.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,448.50 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,153.91 | 2019-2024 | |
| Janssen Biotech, INC. | $729.10 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Allergan, INC. | $702.62 | 2019-2022 | |
| Galderma Laboratories, L.P. | $535.80 | 2019-2025 | Nemluvio, Dysport, Aklief |
| Genzyme Corporation | $463.64 | 2019-2025 | |
| Pfizer INC. | $422.76 | 2019-2020 | |
| Lilly USA, LLC | $396.89 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $290.22 | 2019-2024 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $212.62 | 2019-2024 | Dupixent |
| Dermavant Sciences, INC. | $166.09 | 2023 | Vtama |
| Almirall LLC | $142.65 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $120.87 | 2022 | |
| Arcutis Biotherapeutics, INC. | $120.65 | 2023-2024 | Zoryve |
| Sun Pharmaceutical Industries INC. | $100.81 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $86.62 | 2019 | |
| Amgen INC. | $69.94 | 2019-2023 | Otezla |
| Revance Therapeutics, INC. | $48.54 | 2024 | Daxxify |
| Genentech USA, INC. | $46.78 | 2019 | |
| Dermira, INC. | $36.13 | 2019 | |
| Melinta Therapeutics, LLC | $27.28 | 2019 | |
| Incyte Corporation | $25.27 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $25.12 | 2025 | Valchlor |
| Celgene Corporation | $17.91 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.88 | 2019 | |
| Vyne Pharmaceuticals INC. | $13.09 | 2020 | |
| Dusa Pharmaceuticals, INC. | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Glorioso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.